Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF)

Cell

Volumn 91, Issue 5, 1997, Pages 649-659

  Kamijo, Takehiko ^c   Zindy, Frederique ^c   Roussel, Martine F ^c   Quelle, Dawn E ^b   Downing, James R ^c   Ashmun, Richard A ^c   Grosveld, Gerard ^a   Sherr, Charles J ^c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; GENE LOCUS; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030728468     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)80452-3     Document Type: Article

References (65)

1. Alcorta, D.A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J.C. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA 93, 13742-13747.
2. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684.
3. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Jr., Butel, J.S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
4. INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11, 21-29.
5. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
6. ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA 93, 8541-8545.
7. Fukusawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G.F. (1996) Abnormal centrosome amplification in the absence of p53. Science 271, 1744-1747.
8. Gannon, J.V., Greaves, R., Iggo, R., and Lane, D.P. (1990). Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J. 9, 1595-1602.
9. Gottlieb, T.M., and Oren, M. (1996). p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287, 77-102.
10. Gruis, N.A., van der Velden, P.A., Sandkuijl, L.A., Prins, D.E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., and Frants, R. (1995). Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10, 351-353.
11. Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C.C., and Montesano, R. (1997). Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25, 151-157.
12. Hall, M., and Peters, G. (1996). Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer Res. 68, 67-108.
13. CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16, 859-867.
14. Harvey, D.M., and Levine, A.J. (1991). p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5, 2375-2385.
15. Harvey, M., Sands, A.T., Weiss, R.S., Hegi, M.E., Wiseman, R.W., Pantazis, P., Giovanella, B.C., Tainsky, M.A., Bradley, A., and Donehower, L.A. (1993). In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8, 2457-2467.
16. INK4a-β in mouse lung tumor cells. Oncogene 13, 1885-1891.
17. Hirama, T. and Koeffler, H.P. (1995). Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood 86, 841-854.
18. Holland, E.A., Beaton, S.C., Becker, T.M., Grulet, O.M.C., Peters, B.A., Rizos, H., Kefford, R.F., and Mann, G.J. (1995). Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11, 2289-2294.
19. Hunter, T. and Pines, J. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79, 573-582.
20. Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson, R.T., and Weinberg, R.A. (1994). Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7.
21. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S., III., Johnson, B.E., and Skolnick, M.H. (1994). A cell cycle regulator involved in genesis of many tumor types. Science 264, 436-440.
22. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
23. Kemp, C.J., Wheldon, T., and Balmain, A. (1994) p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet. 8, 66-69.
24. Ko, L.J. and Prives, C. (1996). p53: puzzle and paradigm. Genes Dev. 10, 1054-1072.
25. Koh, J., Enders, G.H., Dynlacht, B.D., and Harlow, E. (1995). Tumour-derived p16 alleles encoding proteins defective in cell cycle inhibition. Nature 375, 506-510.
26. Kubo, Y., Urano, Y., Matsumoto, K., Ahsan, K., and Arase, S. (1997). Mutations of the INK4a locus in squamous cell carcinomas of human skin. Biochem. Biophys. Res. Commun. 232, 38-41.
27. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V., and Kastan, M.B. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Nat. Acad. Sci. USA 89, 7491-7495.
28. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
29. Lloyd, A.C., Obermuller, F., Staddon, S., Barth, C.F., McMahon, M., and Land, H. (1997). Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 11, 663-667.
30. Lukas, J., Parry, D., Aagaard, L., Mann, D.J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. (1995). Retinoblastoma protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature 375, 503-506.
31. INK4a transcript. Cancer Res. 55, 2995-2997.
32. Merlo, A., Herman, J.G., Mao, L., Lee, D.J., Gabrielson, E., Burger, P.C., Baylin, S.B., and Sidransky, D. (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686-692.
33. Naito, M. and DiGiovanni, J. (1989). Genetic background and development of skin tumors. In Carcinogenesis, Vol.III, Skin Tumors: Experimental and Clinical Aspects. C.J. Conti, T.J. Slaga, and A.J.P. Klein-Szanto, eds. (New York: Raven Press), pp. 187-212.
34. INK4 expression. Oncogene 13, 1259-1268.
35. Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K., and Carson, D.A. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756.
36. Noda, A., Ning, Y., Venable, S.F., Pereira-Smith, O.M., and Smith, J.R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211, 90-98.
37. CDKN2 associated with familial melanoma. Mol. Cell. Biol. 16, 3844-3852.
38. Pear, W.S., Nolan, G.P., Martin, L.S., and Baltimore, D. (1993). Production of higher-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392-8396.
39. Pollock, P.M., Pearson, J.V., and Hayward, N.K. (1996). Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chrom. Cancer 15, 77-88.
40. INK4b genes. Oncogene 11, 635-645.
41. Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. (1995b). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000.
42. ARF. Proc. Natl. Acad. Sci. USA 94, 3436-3440.
43. Ranade, K., Hussussian, C.J., Sikorski, R.S., Varmus, H.E., Goldstein, A.M., Tucker, M.A., Serrano, M., Hannon, G.J., Beach, D., and Dracopoli, N.C. (1995). Mutations associated with familial melanoma impair p16INK4 function. Nature Genetics 10, 114-116.
44. Reiners, J.J., Jr., Nesnow, S., and Slaga, T.J. (1984). Murine susceptibility to two-stage skin carcinogenesis is influenced by the agent used for promotion. Carcinogenesis 5, 301-307.
45. Reymond, A., and Brent, R. (1995). p16 proteins from melanomaprone families are deficient in binding to Cdk4. Oncogene 11, 1173-1178.
46. Reznikoff, C.A., Yeager, T.R., Belair, C.D., Savelieva, E., Puthenveettil, J.A., and Stadler, W.M. (1996). Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 56, 2886-2890.
47. Rittling, S.R. and Denhardt, D.T. (1992). p53 mutations in spontaneously immortalized 3T12but not 3T3 mouse embryo cells. Oncogene 7, 935-942.
48. INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol. Cell. Biol. 15, 4745-4753.
49. Serrano, M., Hannon, G.J., and Beach, D. (1993). A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707.
50. Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A. (1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37.
51. INK4a. Cell 88, 593-602.
52. INK4a inactivation in non-small cell lung cancer cell lines. Cancer Res. 55, 6200-6209.
53. Sherr, C.J. (1996). Cancer cell cycles. Science 274, 1672-1677.
54. (MTS1) locus. Cancer Res. 55, 2988-2994.
55. INK4a in primary rat lung tumors. Mol. Cell. Biol. 17, 1366-1374.
56. Tanaka, H., Shimada, Y., Imamura, M., Shibagaki, I., and Ishizaki, K. (1997). Multiple types of aberrations in the p16(INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. Int. J. Cancer 70, 437-442.
57. Todaro, G.J. and Green, H. (1963). Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17, 299-313.
58. Van Deursen, J., Fornerod, M., Van Rees, B., and Grosveld, G. (1995). Cre-mediated site-specific translocation between nonhomologous mouse chromosomes. Proc. Natl. Acad. Sci. USA 92, 7376-7380.
59. INK4 gene in Australian melanoma kindreds. Hum. Mol. Genet. 4, 1845-1852.
60. Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
61. Weinberg, R.A. (1997). The cat and mouse games that genes, viruses, and cells play. Cell 88, 573-575.
62. Wick, S.T., Dubay, M.M., Imanil, I., and Brizuela, L. (1995). Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product p16. Oncogene 11, 2013-2019.
63. Ink4a tumor suppressor protein. Cancer Res. 55, 2503-2506.
64. Yewdell, J.W., Cannon, J.V., and Lane, D.P. (1986). Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59, 444-452.
65. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15, 203-211.